And what a ride it has been … in the past 18 years since Dr. Cribier performed the first-in-man transcatheter aortic valve replacement (TAVR), our fundamental approach to aortic stenosis has undeniably transformed. With increasing experience and technologic iteration, the procedure has also evolved, and what was once met with administrative trepidation and hospital-wide fanfare is now a routine part of daily practice. More recently, the results of the randomized Placement of Aortic Transcatheter Valves (PARTNER) 3 and Evolut Surgical Replacement and Transcatheter Aortic Valve Implantation in Low Risk Patients effectively established TAVR as a viable option for patients with symptomatic trileaflet aortic stenosis at low surgical risk, and TAVR is now an approved therapy for patients across the spectrum of clinical risk. All of this occurred in less than 2 decades.